Drugdiscovery >> Pharmaceutical Companies >> News
3899
Views
GlaxoSmithKline and Novartis sigent a three-part agreemnet - drugdiscovery.com
GlaxoSmithKline and Novartis sigent a three-part agreemnet - drugdiscovery.com


GSK will accquire vaccines of Novartis. This is only one point of the three-part agreement which was signed by the two pharmaceutical giants. Both companies hope development.
Read More >>


Tags: novartis, GKS, vaccination business, pharmaceutical business, pharmaceutical news, pharmaceutical business news. - April 24, 2014
Related Articles
1329
Views
Novartis experiences a solid growth Novartis experiences a solid growth
Perhaps as the result of definitive agreements with GSK and Eli Lilly, Novartis announced that it has produced a solid growth in the subsequent quarter's end. Read More >>

Tags: Novartis, sotck growth, pharmaceutical growth, novartis stocks

1082
Views
Dramatic job-cuts at Novartis Dramatic job-cuts at Novartis
Novartis announced 500 Swiss job cuts. The company started to outsource a large part of its services to India. Read More >>

Tags: novartis, india,jobcut, outsourcing

3778
Views
GlaxoSmithKline and MD Anderson entered a cancer-drug alliance GlaxoSmithKline and MD Anderson entered a cancer-drug alliance
Anderson Cancer Center of Texas University and GlaxoSmithKline announced that they are going to co-operate in further cancer research. The research for immunotherapy is going to be the part of MD Ande Read More >>

Tags: MD Anderson’s Moon Shots Program, Moon Shots program, drug cancer, immunotherapy, drug research, drug development, pharmaceutical companies, GlaxoSmithKline

4088
Views
Novartis has named the new leaders of Alcon and Sandoz Novartis has named the new leaders of Alcon and Sandoz
These new leaders will set the direction for the next phase of growth for our eye care and generics businesses, two of our core growth engines. Read More >>

Tags: biosimilars, pharmaceutical business, pharma leaders, novartis, alcon, sandoz, drug, drug ceo, Chutes and Ladders, Novartis, Sandoz,

2239
Views
Novartis contributes with GSK and changes protfolio Novartis contributes with GSK and changes protfolio
Novartis announced that it is going to transform its portfolio and strenghtens its researches by acquiring products of GSK's oncology wing. Read More >>

Tags: GSK, Novartis, pharmaceutical companies, pharmaceutical news, drug discovery, oncology srugs

2241
Views
Novartis has announced the results of phase 4 INSTEAD study Novartis has announced the results of phase 4 INSTEAD study
Novartis has announced the result of a Phase 4 INSTEAD research made to imporve its new COPD drug. Once-daily indacaterol has shown very promising data. Read More >>

Tags: durg development, INSTEAD Swift study, GSK, Novartis, pharmaceutical news, pharmaceutical companies

2012
Views
A partership between Novartis and Ensemble Therapeutics A partership between Novartis and Ensemble Therapeutics
The two companies have signed the agreement to join their forces in development of experimental therapeutic candidates for the treatment of autoimmune diseases. Read More >>

Tags: Novartis, Ensemble Therapeutics, pact, partnership, inflammation, IL-17, autoimmune diseases

1386
Views
Merck takes part in the campaign to fight schistosomiasis in Sudan Merck takes part in the campaign to fight schistosomiasis in Sudan
Merck KGaA has donated to WHO 2.4 million Sudanese pounds worth schistosomiasis meds - praziquantel tablets for large-scale treatment of schistosomiasis in Sudan. Read More >>

Tags: Merck, donation, WHO, schistosomiasis, praziquantel, Sudan

2126
Views
More bribery allegations in pharma world More bribery allegations in pharma world
According to anonymous whistleblower, Sanofi paid 1.7 million yuan in bribes to 503 doctors in China during 2007, to promote the selling of drugs for treating high blood pressure- Irbesartan and an Ir Read More >>

Tags: bribery, Sanofy, Irbesartan, GlaxoSmithKline, China

585
Views
GSK invests in bioelectronic meds GSK invests in bioelectronic meds
GlaxoSmithKline launched a $50 million venture capital fund that will invest in development of bioelectronic devices that may help treat a number of disorders, including inflammatory bowel disease, rh Read More >>

Tags: GSK, GlaxoSmithKline, investment, biolelectronic devices, bioelectronic medicines

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013